Clinical trials: Dose Administration Aids
HIV Infections, Peripheral Nervous System Diseases
Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy
The purpose of the study is to determine if an investigational drug, NGX-4010 (high-concentration capsaicin patch), is effective in treating painful HIV-associated neuropathy.
- Conditions
- HIV Infections, Peripheral Nervous System Diseases, Pain
- Trial name
- NCT00064623
- Testing
- Capsaicin Dermal Patch
- Where
- 35 sites in United States
- Volunteers
- 300 people
- Sponsor
- NeurogesX
HIV Infections
Comparison of Liquid Kaletra and Low Dose Kaletra Tablets
Kaletra (a combination drug with lopinavir and ritonavir) is one of a few effective medications that are approved and available for young children who are HIV+.
- Trial name
- NCT00762320
- Testing
- Low dose Kaletra tablets
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Phoenix Children's Hospital
HIV-1 Infection
Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women Taking Complera
The purpose of this research study is to evaluate how easy it is for female HIV- positive subjects taking Complera to comply with the dietary requirement using a food diary in the short term (4 weeks) and long term (24 weeks and…
- Trial name
- NCT01701895
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Prema Menezes, PhD, PA-C
HIV Infection
Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg Dose
The investigators' in vitro data suggest that Neurokinin-1 receptor antagonists like aprepitant will decrease the expression of CCR5, an essential co-receptor in the life cycle of HIV, in the surface of macrophages and…
- Trial name
- NCT01300988
- Testing
- Aprepitant
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Pennsylvania
HIV Infections
A Study of CI-1012 in HIV-Infected Patients
The purpose of this study is to see if it is safe and effective to give CI-1012 to HIV-infected patients who do not have any symptoms of the disease. This study also examines how the body handles CI-1012.
- Trial name
- NCT00002196
- Testing
- CI-1012
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- Parke-Davis
Cryptococcal Meningitis, HIV Infections
High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals
Cryptococcal meningitis (CM) is an infection of the membranes covering the brain and spinal cord, caused by the fungus Cryptococcus neoformans.
- Trial name
- NCT00885703
- Testing
- Fluconazole, Amphotericin B
- Where
- 10 sites in United States, India and 6 more
- Volunteers
- 168 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Treatment of Hepatitis C
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infection
Target Population: Hepatitis C Treatment Naïve, non-cirrhotic, Chronic genotype 1 hepatitis C virus (HCV) infected adults that are co-infected with human immunodeficiency virus (HIV)-1and have HCV RNA < 6 x106 IU/mL Duration of…
- Trial name
- NCT02480387
- Testing
- Ledipasvir/Sofosbuvir FDC
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Peter J. Ruane, M.D., Inc.
HIV Infections
An Open-Label Study of Emtricitabine in Combination With Other Antiretroviral Agents in HIV Infected Pediatric Subjects
To obtain safety and efficacy data for antiretroviral regimens containing emtricitabine in HIV-1 infected pediatric subjects. To determine emtricitabine concentrations in HIV-1 infected pediatric subjects and, if necessary, to…
- Trial name
- NCT00642291
- Testing
- Emtricitabine
- Where
- 2 sites in Romania
- Volunteers
- 16 people
- Sponsor
- Gilead Sciences
HIV Infections
Efficacy and Safety of Tenofovir DF/Atazanavir Enhanced With Low Dose of Ritonavir in HIV-Infected Patients
This trial is aimed at studying the antiviral activity, toxicity and pharmacokinetic (PK) interactions of tenofovir DF and atazanavir enhanced with low dose of ritonavir given alone and then concomitantly as part of a salvage…
- Trial name
- NCT00122577
- Testing
- Tenofovir, Atazanavir, Ritonavir
- Where
- France
- Volunteers
- 50 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV Infections, Lipoatrophy
Study Comparing Reducing the Dose of Stavudine Versus Switching to Tenofovir in HIV-Infected Patients Receiving Antiretroviral Therapy
Background: Stavudine-containing regimens are associated with a potential for lipoatrophy and dyslipidemia. We assessed the safety and efficacy of reducing the dose of stavudine compared to switching to tenofovir or maintaining…
- Trial name
- NCT00312832
- Testing
- switching; dose reduction
- Volunteers
- 60 people
- Sponsor
- Hospital Clinic of Barcelona
Dose Administration Aids, Medication Adherence
Testing a Smart Medication Dispenser (Mobili®) to Help People With Chronic Conditions Take Their Medicine
Medication adherence is one of the biggest challenges faced by healthcare systems, especially among people with multiple chronic diseases who take several medications daily.
- Conditions
- Dose Administration Aids, Medication Adherence, Polypharmacy, Technology in Health
- Trial name
- MobiMAd@PT RCT (NCT07175545)
- Testing
- Independent use of the Mobili® Device by patients, overseen by pharmacists
- Where
- Portugal
- Volunteers
- 96 people
- Sponsor
- Lusofona University
Cytomegalovirus Infections, HIV Infections
The Safety and Effectiveness of FIAC in the Treatment of Cytomegalovirus (CMV) in Patients With AIDS
To find oral doses of FIAC (a pyrimidine nucleoside analog) that are effective in treating cytomegalovirus (CMV) viremia in HIV-infected immunocompromised patients; to determine tolerance and safety of FIAC in this patient…
- Trial name
- NCT00000981
- Testing
- Fiacitabine
- Where
- 4 sites in United States
- Volunteers
- 78 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
Evaluate the Tolerability and Therapeutic Effects of Repeated Doses of Autologous T Cells With VRX496 in HIV
The study is intended for individuals who are doing well on HAART therapy. In Step 1 of the trial, individuals will be given up to 6 infusions of the study drug VRX496 to see the effect on viral load and CD4 counts.
- Trial name
- NCT00295477
- Testing
- VRX496
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Pennsylvania
HIV Infections
A Study of Dideoxycytidine Plus Zidovudine in the Treatment of AIDS or Advanced AIDS Related Complex (ARC)
To determine the safety, tolerability, and activity of zidovudine (AZT) and zalcitabine (dideoxycytidine; ddC) and the bloodstream levels of these drugs in patients with AIDS or advanced AIDS-related complex (ARC).
- Trial name
- NCT00000978
- Testing
- Zidovudine, Zalcitabine
- Where
- 2 sites in United States
- Volunteers
- 68 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Pharmacokinetics Study on Nevirapine Resistance in Tanzania
Primary pharmacokinetics of single dose nevirapine the effect of single dose carbamazepine on the pk of single dose nevirapine resistance against nevirapine before and after.
- Trial name
- NCT00294892
- Testing
- carbamazepine and nevirapine, Nevirapine
- Where
- Tanzania
- Volunteers
- 144 people
- Sponsor
- Radboud University Medical Center
Human Immunodeficiency Virus, Chronic Neuropathic Pain
Low Dose Naltrexone for Pain in Patients With HIV
The increased life expectancy of Patients Living With HIV/AIDS (PLWHA) has increased the need for therapies for chronic conditions, such as chronic pain.
- Trial name
- NCT05537935
- Testing
- Low Dose Naltrexone
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Emory University
Hepatitis C Infection, HIV Infection
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection
The purpose of this study was to assess the efficacy of a fixed dose combination (FDC) of glecaprevir/pibrentasvir (G/P) given for 4 weeks for treatment of acute hepatitis C (HCV), with or without HIV-1 coinfection.
- Trial name
- PURGE-C (NCT04042740)
- Testing
- Glecaprevir/Pibrentasvir (G/P)
- Where
- 12 sites in United States, Brazil
- Volunteers
- 45 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Infections
TMC114-C201: A Study to Determine the Antiviral Activity of TMC114 in Patients With Multiple Protease Inhibitor (PI) Resistant Human Immunodeficiency Virus (HIV) Strains
The purpose of this study is to determine the antiviral activity, safety and tolerability of 14 days of different doses of TMC114 to treat HIV-1 positive patients whose condition is failing on a current treatment regimen that…
- Trial name
- NCT00964327
- Testing
- TMC114
- Volunteers
- 42 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Human Immunodeficiency Virus
A Safety Study Of A Single Vaginal Administration Of P2G12 Antibody In Healthy Female Subjects
The purpose of this study is to assess the safety and tolerability of intravaginal administration of P2G12. 11 subjects will receive P2G12/placebo. Three subjects in Group 1 will receive up to 7mg of P2G12, or placebo.
- Trial name
- NCT01403792
- Testing
- P2G12
- Where
- United Kingdom
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of Surrey
HIV-1 Infection
A Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA <50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy Regimen
A prospective, multicenter, open, randomized Phase 2a trial to confirm a sustained virological suppression defined as HIV-RNA <50 copies/ml of 3 different doses of Fozivudine in context to a standard Zidovudine based…
- Trial name
- FATI-01 (NCT01714414)
- Testing
- FZD, 3TC, EFV
- Where
- 2 sites in Côte d’Ivoire, Tanzania
- Volunteers
- 120 people
- Sponsor
- Michael Hoelscher